Per 2016 NCCN guidelines, is the addition of 6 cycles docetaxel now the standard of care for all (NCCN) high and very-high risk prostate cancer patients receiving definitive XRT/ADT?

Last year, the results of RTOG 0521 were presented at ASCO and showed that adjuvant docetaxel led to a small improvement in overall survival for men with high risk prostate cancer. To briefly recap, 563 eligible subjects were randomized to standard-of-care external beam RT (72-75.6Gy, with 46.8 to r...